Compare Medpace Holdings Inc (MEDP) vs Annaly Capital Management, Inc. (NLY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Medpace Holdings Inc vs Annaly Capital Management, Inc. — how do they compare? Medpace Holdings Inc trades at $530.31 (market cap $15.08B), while Annaly Capital Management, Inc. trades at $22.74 (market cap $16.63B). The key difference: Medpace Holdings Inc and Annaly Capital Management, Inc. are close in size by market cap, and Annaly Capital Management, Inc. pays a 13.22% dividend while Medpace Holdings Inc pays none. Which is the better fit depends on your goals.
| MEDP | NLY | |
|---|---|---|
Market Cap | $15.08B | $16.63B |
Sector | Technology | Financials |
52-Week High | $620.59 | $24.40 |
52-Week Low | $308.88 | $19.96 |
Enterprise Value | $14.55B | — |
Dividend Yield | — | 13.22% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
MEDP trades at $527.93, down 1.82% today, with a bullish technical outlook supported by moving averages. The company demonstrates strong profitability with 17.19% net margins and 77.25% ROE, though valuation ratios appear elevated with a P/E of 33.83. Recent earnings have consistently beaten expectations, and cash flow is projected to improve significantly in 2026. However, the stock faces headwinds from ongoing class action lawsuits and mixed analyst sentiment with 73.69% hold ratings.
MEDP presents a mixed investment case with strong fundamental performance offset by legal overhangs and premium valuation. The company's consistent earnings beats and projected cash flow improvement support upside potential, but investors should weigh the legal risks and cautious analyst stance against the robust operational metrics.
NLY trades at $22.73, down 1.22% today, with a bullish technical signal and strong earnings beat history. The stock shows a low P/E of 7.42 and a 13% dividend yield, supported by recent analyst upgrades. Revenue grew to $2.24B in 2025, with net income margin at 91.17%, though cash flow from operations declined to $693M. The consensus price target is $24.80, implying 9% upside.
Outlook remains positive given earnings momentum and high yield, but risks include interest rate sensitivity and elevated debt-to-asset ratio of 23.55. Institutional sentiment is bullish with 57% buy ratings, though macroeconomic shifts could pressure mortgage REIT performance.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Medpace Holdings Inc
Medpace Holdings, Inc. is a full-service clinical contract research organization (CRO) that provides comprehensive and scientifically-driven clinical development services to the biotechnology, pharmaceutical, and medical device industries. The company specializes in conducting global clinical trials for new drug and medical device approvals. Medpace's model emphasizes therapeutic expertise and a highly integrated approach to accelerate the clinical development process for its clients.
Read more on MEDP →About Annaly Capital Management, Inc.
Annaly Capital Management Inc is an American mortgage real estate investment trust. The company segments its operations into Residential and Commercial real estate investments. While Annaly's Residential assets are primarily comprised of agency mortgage-backed securities and debentures, it is primarily invested in commercial mortgage loans and mortgage-backed securities in its Commercial unit through its subsidiary, Annaly Commercial Real Estate Group. Agency mortgage-backed securities and debentures make up the majority of the company's overall portfolio. Most of the company's counterparties are located in the U.S. Annaly generates nearly all of its revenue from the spread between interest earned on its assets and interest payments made on its borrowings.
Read more on NLY →
